Peer Review History

Original SubmissionAugust 24, 2021

Attachments
Attachment
Submitted filename: PLOS ONE revise authors reply konishi (1).docx
Decision Letter - Yoshiaki Taniyama, Editor

PONE-D-21-24785Circulating sLR11 levels predict severity of pulmonary hypertension due to left heart diseasePLOS ONE

Dear Dr. Konishi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

One of the reviewer pointed out some statistical problems, so please respond them.

Please submit your revised manuscript by Dec 03 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Yoshiaki Taniyama, MD, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for providing the following Funding Statement:  

Tsukuba Research Institute, Sekisui Medical Co. Ltd. provided support in the form of salaries for Hiroyuki Ebinuma. The specific roles of these authors are articulated in the ‘author contributions’ section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

We note that one or more of the authors is affiliated with the funding organization, indicating the funder may have had some role in the design, data collection, analysis or preparation of your manuscript for publication; in other words, the funder played an indirect role through the participation of the co-authors. 

If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study in the Author Contributions section of the online submission form. Please make any necessary amendments directly within this section of the online submission form.  Please also update your Funding Statement to include the following statement: “The funder provided support in the form of salaries for authors [insert relevant initials], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.” 

If the funding organization did have an additional role, please state and explain that role within your Funding Statement. 

Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

3. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This version has been satisfactorily responded to my original comments. The conclusion is supported by the results presented in this manuscript. The methods and discussion are well written. This reviewer has no further comments.

Reviewer #2: The authors conduct the analysis of 34 patients to examine whether sLR11 is associated with PH in PH-LHD with 5 years follow-up. The results showed the association between sLR11 and the severity of PH.

1. Statistical analysis: “baseline characteristics….using two-sided two-sample T-tests for normally distributed continuous variables”. Are all baseline characteristics normally distributed? If not, how about non-normally distributed variables?

2. Statistical Analysis: “Raw counts and percentages are described as mean and standard deviation”. Please clarify what this statement!

3. Results: 28 out of 66 MR patients were excluded from the original enrolled sample. Are there any characteristics difference between these 28 and the remaining patients?

4. Results: “Median age was 64.8±13.1”. So 64.8 is median age but what 13.1 is? IQR? Please clarify this. Similar question applies to other reported information.

5. Results: There are many typos or errors here and there!! This is quite a surprising to see for a revised manuscript. Also, it might be benefit to use English editing as well. To name some examples,

a. “there was not a variable that had 0.95 multiple correlation coefficient > 0.95.” Please clarify what this statement means?

b. “We defined to the objective variable was mPAP and selected an explanation variable which is high in degree of influence on an objective variable that cardiovascular risk factor.” Please clarify what this statement means.

6. Results. “Based on our previous normal human sLR11 level of…, we established an upper limit of normal for sLR11 of 9.4..” Please provide more detail how this was establish? If this criteria is from previous work, please cite appropriate reference.

7. Tables 1 and 3. “data are presented as n,…mean,…or median.” Please make clear notes which variables were presented in mean and which in median.

8. Table 2. Please add degree of freedom information for the F-statistic. Otherwise, it doesn’t have any meaning with only F-stat.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Responses to Comments

Reviewer #1:

We wish to express our deep appreciation to Reviewer #1.

Reviewer #2:

Thank you very much for providing important comments.

1. Statistical analysis: “baseline characteristics….using two-sided two-sample T-tests for normally distributed continuous variables”. Are all baseline characteristics normally distributed? If not, how about non-normally distributed variables?

Thank you for raising this important issue. We have mentioned in the revised text that the Mann-Whitney U test was applied for the analysis of non-normally distributed continuous variables.

2. Statistical Analysis: “Raw counts and percentages are described as mean and standard deviation”. Please clarify what this statement!

What we meant was that data in the form of raw counts and percentages described in the text are mean values ± standard deviation (SD).

3. Results: 28 out of 66 MR patients were excluded from the original enrolled sample. Are there any characteristics difference between these 28 and the remaining patients?

The 28 patients were excluded on the basis that they could not be tracked in the electronic medical records. As a result, we do not have data with which to compare excluded and analyzed patients.

4. Results: “Median age was 64.8±13.1”. So 64.8 is median age but what 13.1 is? IQR? Please clarify this. Similar question applies to other reported information.

We apologize for this error. We have deleted the median value and provided the data as mean ± standard deviation.

5. Results: There are many typos or errors here and there!! This is quite a surprising to see for a revised manuscript. Also, it might be benefit to use English editing as well. To name some examples, a. “there was not a variable that had 0.95 multiple correlation coefficient > 0.95.” Please clarify what this statement means?

Our manuscript had undergone English proofreading before the first submission, but the revised text has undergone further proofreading.

b. “We defined to the objective variable was mPAP and selected an explanation variable which is high in degree of influence on an objective variable that cardiovascular risk factor.” Please clarify what this statement means.

Thank you for this comment. We have added a reference for the cardiovascular risk factor after this sentence.

6. Results. “Based on our previous normal human sLR11 level of…, we established an upper limit of normal for sLR11 of 9.4..” Please provide more detail how this was establish? If this criteria is from previous work, please cite appropriate reference.

We have cited our previous report (Ref. 15) showing that the mean (�SD) serum sLR11 level in healthy individuals was 7.8 ± 1.6 ng/mL.

7. Tables 1 and 3. “data are presented as n,…mean,…or median.” Please make clear notes which variables were presented in mean and which in median.

As noted in response to Comment 4, values have been provided as means ± standard deviations.

8. Table 2. Please add degree of freedom information for the F-statistic. Otherwise, it doesn’t have any meaning with only F-stat.

Thank you for this comment. We have added degrees of freedom to Table 2.

Attachments
Attachment
Submitted filename: response.docx
Decision Letter - Yoshiaki Taniyama, Editor

Circulating sLR11 levels predict severity of pulmonary hypertension due to left heart disease

PONE-D-21-24785R1

Dear Dr. Konishi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Yoshiaki Taniyama, MD, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This reviewer have no further comments on the revised manuscript. The manuscript was well revised and should be published as soon as possible.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Formally Accepted
Acceptance Letter - Yoshiaki Taniyama, Editor

PONE-D-21-24785R1

Circulating sLR11 levels predict severity of pulmonary hypertension due to left heart disease

Dear Dr. Konishi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Yoshiaki Taniyama

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .